Illumina opened lower at $255.77, compared with its previous close of $290.06. In the last trading session, the stock traded between $245.00 and $256.09. It showed a downward intraday trend.
return calculator
Time Period
An investment of $100 made 5 years ago in Illumina is now worth
$ 59.78
resulting in a loss of
$ 40.22 (40.22%)
invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 16 Analysts
Buy
56.25%
Hold
25%
Sell
18.75%
Markets Today
Today's Change
$-41.93 (-14.46%)
Day High
$256.09
Day Low
$245.00
Day Open
$255.77
Prev Close
$290.06
Volume
14,21,766
1W Return
-8.10%
1M Return
-8.80%
3M Return
27.49%
6M Return
106.14%
1Y Return
161.11%
Fundamentals
Market Cap ($ Mn)
37,468
PE Ratio
40.22
PB Ratio
11.47
PEG Ratio
75.79
ROE
35.12%
ROCE
24.51%
EPS (TTM)
$1.37
Investment Returns
1 Week
-8.10%
1 Month
-8.80%
3 Months
27.49%
6 Months
106.14%
9 Months
65.76%
Financials
Quarterly
All values in $ Mn
1.0K
Mar 25
1.1K
Jun 25
1.1K
Sep 25
1.2K
Dec 25
1.1K
Mar 26
1.2K
Jun 26
Updates
15Oct
Illumina delivers 16.89% annualized return over last 15 years
Illumina recorded an average annual return of 16.89% over the past 15 years. The stock outperformed the market by 3.81% on an annualized basis. A $100 investment from 15 years ago is now valued at $1,066.70. Current market capitalization stands at $42.30 billion.
15 days ago
23Sep
Illumina shares turn $1,000 into $15,149.25 over 20 years
A $1,000 investment in Illumina 20 years ago is now worth $15,149.25. Shares delivered an average annual return of 14.65%. Illumina outperformed the market by 5.48% on an annualized basis. Current market capitalization stands at $37.84 billion.
1mo ago
18Sep
Illumina Q2FY26 Results: Revenue up 9.5% to $1.16 billion
Revenue rose 9.5% YoY to $1.16 billion, driven by clinical demand. Non-GAAP EPS grew 10% to $1.31, beating prior guidance. Full-year revenue and EPS guidance raised amid strong NovaSeq X placements. Clinical consumables grew 15% ex-China; research segment declined 7%. Free cash flow was $162 million; share buybacks totaled $122 million.
1mo ago
6Aug
Illumina delivers 13.26% annualized return over 20 years
Illumina has achieved a 13.26% annualized return over 20 years, beating the market by 3.84%. A $1,000 investment from two decades ago is now worth $12,070.63, with the company currently valued at $30.65 billion and trading at $200.46 per share.
2mo ago
31Jul
Illumina Latest Results: Raises FY2026 Adj EPS and Sales Guidance
Illumina raises FY2026 adjusted EPS guidance to $5.30-$5.40 and sales guidance to $4.600B-$4.640B. Both new ranges exceed analyst estimates of $5.23 for EPS and $4.566B for sales, reflecting stronger expected performance.
3mo ago
17Jul
Illumina price targets raised to $210 by Leerink, $190 by Canaccord
Leerink Partners analyst Puneet Souda maintained an Outperform rating on Illumina, raising the price target to $210 from $175. Canaccord Genuity analyst Kyle Mikson kept a Hold rating while increasing the price target to $190 from $140.
